COMPOSITIONS AND METHODS FOR THE REDUCTION OR PREVENTION OF HEPATIC STEATOSIS

• US 20160067201A1
• Filed: 09/02/2015
• Published: 03/10/2016
• Est. Priority Date: 02/27/2014
• Status: Active Grant

• Current Assignee: Nusirt Sciences, Inc.
• Original Assignee: Nusirt Sciences, Inc.
• Inventors: Zemel, Michael, Bruckbauer, Antje
• Granted Patent: US 9,872,844 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/05 Phenols cannabinoids A61K31/658
• CPC Class Codes: A61K 31/155 Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/352 condensed with carbocyclic rings, e.g. methantheline cannabinoids A61K31/658
• CPC Class Codes: A61K 31/4439 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole nicotine A61K31/465
• CPC Class Codes: A61K 31/4985 Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 31/522 having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• CPC Class Codes: A61K 31/53 having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine melarsoprol A61K31/555 ; with four nitrogen atoms A61K31/495
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Methods useful for reducing or preventing non-alcoholic steatohepatitis or hepatic steatosis are provided herein. Such methods may comprise administering to a subject in need thereof a sirtuin pathway activator and/or PDE5 inhibitor alone or in combination with an amount of a branched amino acid in free amino acid form, or a metabolite thereof. Also provided herein are compositions and kits for practicing any of the methods described herein.

Claims

1-72. -72. (canceled)

73. A method of reducing non-alcoholic steatohepatitis (NASH) in a subject in need thereof, comprising administering to the subject a composition comprising:

a) an amount of leucine in the form of a free amino acid and/or metabolite thereof; and

b) an amount of one or more sirtuin pathway activators.

74. The method of claim 73, wherein component (b) comprises one or more sirtuin pathway activators selected from the group consisting of an AMPK activator, a PGC-1α

activator, a PDE5 specific inhibitor, a biguanide and a thiazolidinedione.

75. The method of claim 73, wherein the amount of component (a) administered to the subject is about 0.25-3 g/day of leucine in the form of a free amino acid, and/or about 0.2-3 g/day of leucine metabolite.

76. The method of claim 73, wherein the leucine metabolite thereof is β

-hydroxy β

-methylbutyrate (HMB) or keto-isocaproic acid (KIC).

77. The method of claim 73, wherein component (b) comprises sildenafil.

78. The method of claim 73, wherein the component (a) comprises leucine existing in form of a free amino acid and the component (b) comprises metformin.

79. The method of claim 73, wherein when component (a) is leucine and component (b) is a selective PDE inhibitor, the molar ratio of the leucine to the PDE 5 specific inhibitor in the composition is at least about 20.

80. The method of claim 74, wherein component (b) comprises a thiazolidinedione.

81. The method of claim 80, wherein the thiazolidinedione comprises rosiglitazone or pioglitazone.

82. The method of claim 80, wherein the amount of thiazolidinedione administered to the subject is about 0.1-4 mg of rosiglitazone or about 0.1-45 mg of pioglitazone.

83. The method of claim 73, wherein component (b) comprises a PDE5 specific inhibitor selected from the group consisting of icariin, sildenafil, tadalafil, vardenafil, avanafil, lodenafil, mirodenafil and udenafil.

84. The method of claim 73, wherein component (b) comprises an amount of a PDE5 specific inhibitor selected from the group consisting of about 1-2000 mg/day of icariin, about 0.05-100 mg/day of sildenafil, about 0.01-20 mg/day of tadalafil, about 0.01-20 mg/day of vardenafil, about 1-200 mg/day of avanafil, about 1-200 mg/day of lodenafil, about 1-100 mg/day of mirodenafil, about 1-200 mg/day of udenafil, and about 1-2000 mg/day of zaprinast.

85. The method of claim 73, wherein component (b) comprises at least two sirtuin pathway activators.

86. The method of claim 73, wherein component (b) comprises a PDE5 specific inhibitor and a biguanide.

87. The method of claim 86, wherein the PDE5 specific inhibitor comprises sildenafil.

88. The method of claim 86, wherein the biguanide comprises metformin.

89. The method of claim 88, wherein a sub-therapeutic amount of metformin is administered to the subject.

90. The method of claim 88, wherein the amount of metformin administered to the subject is about 10-1000 mg/day.

91. The method of claim 86, wherein component (a) comprises leucine in the form of a free amino acid and (b) comprises sildenafil and metformin.

92. The method of claim 91, wherein the composition administered to the subject is formulated in a unit dose, and wherein the composition comprises:

(i) component (a) comprising about 900-1200 mg of leucine in the form of a free amino acid; and

(ii) component (b) comprising about 200-550 mg of metformin and about 0.1-10 mg of sildenafil.

93. The method of claim 92, wherein the unit dose is administered twice a day.

94. The method of claim 92, wherein the components of the unit dose are co-administered to the subject simultaneously as a single composition or sequentially.

95. The method of claim 73, wherein the subject has been diagnosed with the non-alcoholic steatohepatitis (NASH), or exhibits a non-alcoholic fatty liver disease (NAFLD) selected from the group consisting of non-alcoholic fatty liver (NAFL), NASH-related cirrhosis and hepatic steatosis.

96. The method of claim 73, comprising administering the composition to the subject twice daily and the liver mass of the subject is decreased by 25% within 6 weeks.

97. The method of claim 73, wherein the composition is substantially free of one or more free amino acids selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine.

98. The method of claim 73, wherein the administering of (a) and (b) reduces non-alcoholic steatohepatitis (NASH) to a greater extent than administration of (a) alone, thereby reducing non-alcoholic steatohepatitis (NASH) in the subject.

99. The method of claim 98, wherein the non-alcoholic steatohepatitis (NASH) in the subject is evidenced by an accumulation of hepatic fat, fibrosis and/or inflammation detectable by one or more methods selected from the group consisting of ultrasonography, computed tomography (CT), magnetic resonance imaging, magnetic resonance spectroscopy (MRS), magnetic resonance elastography (MRE), transient elastography (TE), hepatic steatosis, inflammation and/or fibrosis detected by biopsy, and detection of a biomarker indicative of liver damage.

100. The method of claim 99, wherein the biomarker indicative of liver damage is elevated serum alanine aminotransferase, aspartate aminotransferase, and/or cytokeratin 18.

101. A method of preventing non-alcoholic steatohepatitis (NASH) in a subject exhibiting a propensity to hepatic steatosis, comprising administering to the subject prior to manifestation of a hepatic steatosis symptom:

a. an amount of leucine in the form of a free amino acid and/or metabolite thereof; and

b. an amount of one or more sirtuin pathway activators.

102. The method of claim 101, wherein the composition administered to the subject is formulated in a unit dose, and wherein the composition comprises:

(i) component (a) comprising about 900-1200 mg of leucine in the form of a free amino acid; and

(ii) component (b) comprising about 200-550 mg of metformin and about 0.1-10 mg of sildenafil.

103. The method of claim 102, wherein the components of the unit dose are co-administered to the subject simultaneously as a single composition or sequentially, and the unit dose is administered twice a day.